Baidu
map

甲状腺结节手术范围合理选择

2015-06-02 代文杰,徐德全,殷越 中国实用外科杂志

2009 年,美国甲状腺协会(American Thyroid Associa- tion,ATA)发表了第三版《ATA 甲状腺结节和分化型甲状腺 癌诊治指南》(以下简称“2009 版指南”)[1]。在过去的几年 间,出现了许多诊断和治疗甲状腺结节和分化型甲状腺(DTC)的最新证据。更多的问题和争论焦点逐渐被临床医 师提出,包括诊断评估甲状腺结节的最佳方法、甲状腺结 节的手术范围、甲状腺微

2009 年,美国甲状腺协会(American Thyroid Associa- tion,ATA)发表了第三版《ATA 甲状腺结节和分化型甲状腺 癌诊治指南》(以下简称“2009 版指南”)[1]。在过去的几年 间,出现了许多诊断和治疗甲状腺结节和分化型甲状腺(DTC)的最新证据。更多的问题和争论焦点逐渐被临床医 师提出,包括诊断评估甲状腺结节的最佳方法、甲状腺结 节的手术范围、甲状腺微小癌的临床处理、甲状腺术后内 分泌治疗的合理应用、甲状腺癌 131I 治疗的适用人群以及甲 状腺癌靶向治疗的应用等。2012 年基于临床循证医学证 据、立足国情及参照国内外众多专家意见,我国首部《甲状 腺结节和分化型甲状腺癌诊治指南》(以下简称“国内指 南”)得以出版[2]。近年来,甲状腺外科治疗理念又有了许 多更新。2015 年 ATA 即将发布新版 ATA 指南(以下简称 “新版 ATA 指南”),其中对于甲状腺结节的手术范围又有 了新认识。本文将结合 2009 版指南以及国内指南对新版 ATA 指南中关于甲状腺结节手术范围更新内容进行对比解读。

1 良性甲状腺结节的手术治疗

甲状腺结节是甲状腺外科最常见的疾病,定义为各种 原因所致甲状腺内出现一个或多个组织结构异常的团块, 可被影像学检查与周围的甲状腺组织区分开,临床可触及 或不可触及。在甲状腺结节中,良性病变约占 95%,恶性病 变仅占 5%左右。2009 版指南对于甲状腺结节诊治就已强 调初始评估的重要性,包括细针穿刺细胞学检查(fine nee-dle aspiration,FNA)、临床超声以及实验室检查。2009 版指 南推荐如果结节的细胞学检查结果为良性,则不需要进一 步的诊断性检查或治疗,但应对病人进行随访;如果随访 通过触诊或超声检查发现结节增大(实性结节或囊实性结 节中的实性部分的体积改变>50%或至少两个方位的尺寸 增加 20%且至少增加 2 mm),应在超声引导下再次行 FNA 检查。对于反复出现良性囊性结节增大或复发的病人,可 根据病人症状和综合美容因素考虑行手术治疗或行经皮 乙醇注射治疗(percultaneous ethanol injection,PEI)。对于 性质未定的甲状腺结节如肿瘤直径较大(>4 cm)、活检结果 示明显的不典型改变或可疑甲状腺乳头状癌(PTC)、有甲 状腺癌家族史或放射线暴露史应考虑甲状腺全切除;如双 侧叶均存在结节或虽仅一侧有性质未定的结节而希望双 侧叶切除以避免将来对侧叶的手术,可考虑给予甲状腺全 或近全切除。从总体上看,2009 版 ATA 指南对于甲状腺结 节的处理主要基于 FNA 和(或)超声诊断,其对于 FNA 明确 诊断为良性甲状腺的结节治疗策略主要以观察或介入等 非手术治疗方法为主。

相比 2009 版 ATA 指南,国内指南对于良性甲状腺结节 的治疗给予了明确的手术指征。国内指南推荐甲状腺结 节下述情况可考虑手术治疗:(1)出现结节明显相关的局 部压迫症状;(2)合并甲状腺功能亢进,内科治疗无效者;(3)肿物位于胸骨后或纵隔内;(4)结节进行性生长,临床 考虑有恶变倾向或合并甲状腺癌高危因素。因外观或思 想顾虑过重影响正常生活而强烈要求手术者,可作为手术 的相对适应证。对于良性甲状腺结节的手术范围,国内指 南强调在彻底切除甲状腺结节的同时,尽量保留正常甲状 腺组织。建议慎重应用全(近全)甲状腺切除术式。后者 的适应证为:结节弥漫性分布于双侧甲状腺,导致术中难 以保留较多正常甲状腺组织。同时术中应注意保护甲状 旁腺和喉返神经。实际上,国内指南虽然对需进行手术治 疗的甲状腺结节规定了明确的手术指征,然而对于具体的 手术范围还是给临床医生留出了更多的选择空间。这种 选择空间使得良性甲状腺结节在我国实际上存在 5 种术 式,分别为甲状腺部分切除术、甲状腺大部切除术、甲状腺 腺叶切除术、甲状腺近全切除术以及甲状腺全切除术。从 手术技巧、难度以及术后近期并发症发生率的角度看,甲 状腺部分切除术及甲状腺大部切除术相对于其他 3 种术式 更易操作。这也使得甲状腺部分切除术和大部切除术成 为了我国基层医院的主流术式。值得注意的是,对于良性 需手术治疗的甲状腺结节,欧美的主流术式仍为甲状腺腺 叶切除和甲状腺全切除术。主流术式选择的差异更多的 原因在于甲状腺部分切除术以及大部切除术所产生的较 高的术后复发率。一旦病人出现复发,再次手术不仅给病 人本人及家庭带来了更多的心里精神压力,同时也增加了 手术本身的难度和副损伤风险的发生。相信随着我国甲 状腺外科专业化和专科医生培养制度的进一步推进,我国 对于良性甲状腺结节的手术方式将能逐步与国际接轨。

实际上,新版 ATA 指南对于大部分良性甲状腺结节仍 不支持手术治疗。新版 ATA 指南指出,对于持续增长且反 复 FNA 检查仍为良性的甲状腺结节,如结节体积较大(直 径>4 cm),产生压迫症状,或病人因结节产生焦虑症状才需 考虑手术治疗。值得注意的是新版 ATA 指南对于甲状腺 结节的界定更加严格并强调基因分析的作用。对于伴有 意义不明的异型性病变或意义明确的滤泡性病变(atypia of undetermined significance/follicular lesion of undetermined significance,AUS/ FLUS)的甲状腺结节,应首选进行反复 FNA 和(或)基因分子学检测。对于不能或不适合进行反 复 FNA 和(或)分子学检测病人,应依据临床存在的危险因 素、超声影像学表现和病人的意愿选择进行随访或诊断性 外科病灶切除。新版 ATA 指南强调对于性质不明病变提 出联合检测基因突变和重组(BRAF,NRAS,HRAS,KRAS, PET/PTC,PAX8/PPAR γ)可 进 一 步 提 高 诊 断 敏 感 度(63%~80%)[3];基因检测结果如 BRAF,RET/PTC 或 PAX8/ PPARγ阳性时,100%的 AUS/FLUS 病例为恶性结局。然而 RAS 突变阳性时,84%的病例为恶性倾向,仍有 16%的病例 可能为良性滤泡性腺瘤。须注意的是,行 FNA 检查时,在 穿刺过程中增加样本细胞量确认环节十分重要,不仅可以 提高细胞病理学诊断率,同时确保了 FNA 诊断不清时足以 提取基因进行分子标记物检测。

2 DTC 的外科治疗

2.1 DTC 原发灶处理 DTC 占甲状腺癌的绝大多数,其预 后较好,10 年存活率为 80%~90%。外科手术是 DTC 首要 治疗手段[4]。ATA 指南与国内指南对于 DTC 的手术方式建 议是一致的,主要包括两类:全(近全)甲状腺切除和单侧 甲状腺腺叶切除(有或无峡部切除)。对于活检确诊的 DTC 手术指征,新版 ATA 指南与国内指南相似,但与 2009 版 ATA 指南相比变化较大(各版 DTC 手术指征详见表 1)。新 版 ATA 指南对于手术指征的把握主要以癌灶直径大小进 行区分。与 2009 版 ATA 指南甲状腺全切除要求肿瘤直 径>1 cm 相比,新版指南将肿瘤直径要求须>4 cm。对于 直径 1~4 cm 肿瘤的处理,新版 ATA 指南将其列为全切或 腺叶切除的相对适应证,其做法与国内指南几乎一致。这 也提示外科医生可根据自身专业技能水平选择更适合自 身的手术方式,让病人获益最大。

新版 ATA 指南指出,对于部分 DTC 病人,行双侧甲状 腺切除和单侧叶甲状腺切除的远期临床结局差异无统计 学意义[5-6]。然而,行单侧叶甲状腺切除的病人,因保留了 残余腺叶的功能可有效避免须终生服用外源性甲状腺激 素的后续治疗。因此,新版 ATA 指南支持对于部分 DTC 病 人仅行单侧叶甲状腺切除。对于癌灶直径 1~4 cm、不合 并腺外浸润、临床 cN0(术前无淋巴结转移)期病人,初始手 术方案可行甲状腺全(近全)切除或单侧腺叶切除。对于 二者术式选择的区别,新版 ATA 指南强调对于低危甲状腺 滤泡状癌和乳头状癌,初始治疗选择单侧甲状腺腺叶切除,病人可能获益更大。然而,如为了进行放射碘治疗、更 好随访疾病以及出于病人个人意愿,行甲状腺全切更佳。



近年来,甲状腺微小癌(肿瘤最大直径≤1 cm)的发生 率逐年增加。2014 年世界卫生组织(WHO)公布的全球癌 症报告指出甲状腺癌新发病例中>50%为甲状腺微小乳头 状癌(papillary microcarcinomas,PTMC)。PTMC 因其预后良 好,可为严密观察或外科手术治疗。对于 PTMC 的治疗, ATA 指南与国内指南观点一致,均建议行外科手术治疗。 值得注意的是,2009 版 ATA 指南对于年龄>45 岁的微小癌 均建议行甲状腺全切除,而国内指南与新版 ATA 指南对于 大部分微小癌处理仍推荐腺叶切除。新版 ATA 指南强调 甲状腺患侧腺叶切除对于微小、单发、腺体内病变且无头 颈部放射史、家族性甲状腺癌史和明显的颈淋巴结肿大的 病人是有效的治疗[7]。

2.2  DTC 颈淋巴结的手术治疗  临床上许多伴颈淋巴结 转移的病人,术前影像学或术中检查可无明显异常。但对 病人进行预防性颈淋巴结清扫时,可能将病人从临床 cN0期转变为病理学 cN1a 期或将>45 岁病人的美国癌症联合 委员会(AJCC)分期由Ⅰ期提升为Ⅲ期[8]。病理分期的改 变可能会影响病人预后,改变复发风险。因此,规范且准 确的颈淋巴结处理原则对于甲状腺外科治疗尤为重要。 对于 DTC 颈淋巴结的清扫,2009 版 ATA 指南以及国内指南 总体原则均是在有效保护甲状旁腺和喉返神经的基础上, 对 DTC 病人行中央区淋巴结(Ⅵ区)清扫。对于临床明确 颈侧区淋巴结转移的病人,建议行颈侧区淋巴结清扫。国 内 指 南 更 是 指 出 对 于 临 床 颈 部 非 中 央 区 淋 巴 结 转 移(cN1b)的 DTC 病人,建议行颈侧区淋巴结清扫;部分临床 颈部中央区淋巴结转移(cN1a)病人行择区性颈部淋巴结 清扫术。值得注意的是,2009 版 ATA 指南对于不清扫淋巴 结的情况也给出了具体指征:对那些较小(T1、T2)、非侵袭 性、淋巴结未受累的 PTC 或大部分滤泡状癌病人,可考虑只 行甲状腺全(近全)切除术而无须行预防性淋巴结清扫。

新版 ATA 指南指出预防性颈淋巴结清扫可以改善疾 病相关存活率,降低疾病复发风险,同时可保证 131I 治疗有效性,但并非所有 DTC 都能获益。一些研究显示预防性颈 淋巴结清扫对于部分甲状腺癌病人不但没有改善远期预 后,反而增加了低钙血症等并发症[9-10]。因此,新版 ATA 指 南提出了须预防性颈淋巴结清扫的指征。新版指南推荐 的 DTC 颈淋巴结处理指征包括:(1)术前临床检查提示中 央区淋巴结转移病人,须行治疗性中央组淋巴结(Ⅵ区)清 扫;(2)甲状腺乳头状癌病人如术前临床检查无淋巴结转 移(cN0 期),但甲状腺癌原发灶为 T3 或 T4 期,或者术前临 床检查提示颈侧区淋巴结转移(cN1b 期),或者中央组淋巴 结累及情况会影响后续治疗,建议行预防性中央组淋巴结 清扫;(3)对于有病理证实颈侧区淋巴结转移的病人,推荐 行治疗性颈侧区淋巴结清扫。值得注意的是新版 ATA 指 南指出如术前超声发现直径>8~10 mm 的可疑淋巴结,应 推荐行 FNA 检查及洗脱液甲状腺球蛋白(Tg)检查。

3 结语

外科治疗模式已从“可耐受最大治疗”转变到“最小有 效治疗”[11],新版 ATA 指南为甲状腺结节治疗提出了新的 规范化诊治方案,尤其凸显了治疗的“有效性”。其更加注 重超声检查联合 FNA 及分子诊断技术对甲状腺结节及颈 淋巴结累及情况进行术前评估,使甲状腺手术更加有理可 依。同时新版指南对于甲状腺癌的手术指征要求更加严 格,对于甲状腺癌腺体的全切除要求,已由 2009 版 ATA 指 南的癌灶直径>1 cm 改为直径>4 cm,同时单侧腺叶切除术 式逐渐被外科专家认可。其体现了对于低危甲状腺癌病 人尽量保留腺体功能、避免不必要治疗的外科理念。总之, 新版 ATA 指南对于 DTC 手术态度的改变,不仅是 DTC 总体 预后较好的体现,更强调了对于 DTC 病人应注重病人术后 生存质量的提高。

原始出处:

代文杰,徐德全,殷越.甲状腺结节手术范围合理选择.中国实用外科杂志,2015, 6, 35(6):604-607.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (9)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=214403, encodeId=c23921440326, content=学习了,特别是对甲状腺微小癌的外科处理。, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NebL6HUuazlWRDicKU30ib7MWct2QQNWiao1ntOx2x5WUHGVw7R8NBdVuXbznuDsHKg3ImrnRyHGr8WSmKTnycicXEf/0, createdBy=bcd81373695, createdName=dpbl_zlh, createdTime=Fri Jun 23 15:10:49 CST 2017, time=2017-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=113575, encodeId=65d71135e5de, content=收藏学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160616/IMG5762A3665DC7B3997.jpg, createdBy=df0a1649089, createdName=ys2323, createdTime=Thu Sep 08 10:20:00 CST 2016, time=2016-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=25877, encodeId=677a258e79d, content=哈医大的啊, beContent=null, objectType=article, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0fb31625608, createdName=雨人, createdTime=Wed Jun 03 22:14:00 CST 2015, time=2015-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=25804, encodeId=3b472580494, content=新版的信息是从哪儿来的?子虚乌有?新版的ATA都没有不出来呢!!求说法, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=jasonuclear, createdTime=Tue Jun 02 23:19:00 CST 2015, time=2015-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=25799, encodeId=302c25e99b1, content=如何调理呢, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=06b51627034, createdName=荔枝, createdTime=Tue Jun 02 21:25:00 CST 2015, time=2015-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=25795, encodeId=e1cb25e951d, content=高大上, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=MedSci客户端网友, createdTime=Tue Jun 02 21:17:00 CST 2015, time=2015-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=25796, encodeId=200025e96b1, content=有点听不懂, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=MedSci客户端网友, createdTime=Tue Jun 02 21:17:00 CST 2015, time=2015-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=25797, encodeId=668025e97c7, content=我有家人是患者, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=MedSci客户端网友, createdTime=Tue Jun 02 21:17:00 CST 2015, time=2015-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=25798, encodeId=95fa25e9864, content=那么如何调理呢, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=MedSci客户端网友, createdTime=Tue Jun 02 21:17:00 CST 2015, time=2015-06-02, status=1, ipAttribution=)]
    2017-06-23 dpbl_zlh

    学习了,特别是对甲状腺微小癌的外科处理。

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=214403, encodeId=c23921440326, content=学习了,特别是对甲状腺微小癌的外科处理。, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NebL6HUuazlWRDicKU30ib7MWct2QQNWiao1ntOx2x5WUHGVw7R8NBdVuXbznuDsHKg3ImrnRyHGr8WSmKTnycicXEf/0, createdBy=bcd81373695, createdName=dpbl_zlh, createdTime=Fri Jun 23 15:10:49 CST 2017, time=2017-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=113575, encodeId=65d71135e5de, content=收藏学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160616/IMG5762A3665DC7B3997.jpg, createdBy=df0a1649089, createdName=ys2323, createdTime=Thu Sep 08 10:20:00 CST 2016, time=2016-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=25877, encodeId=677a258e79d, content=哈医大的啊, beContent=null, objectType=article, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0fb31625608, createdName=雨人, createdTime=Wed Jun 03 22:14:00 CST 2015, time=2015-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=25804, encodeId=3b472580494, content=新版的信息是从哪儿来的?子虚乌有?新版的ATA都没有不出来呢!!求说法, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=jasonuclear, createdTime=Tue Jun 02 23:19:00 CST 2015, time=2015-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=25799, encodeId=302c25e99b1, content=如何调理呢, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=06b51627034, createdName=荔枝, createdTime=Tue Jun 02 21:25:00 CST 2015, time=2015-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=25795, encodeId=e1cb25e951d, content=高大上, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=MedSci客户端网友, createdTime=Tue Jun 02 21:17:00 CST 2015, time=2015-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=25796, encodeId=200025e96b1, content=有点听不懂, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=MedSci客户端网友, createdTime=Tue Jun 02 21:17:00 CST 2015, time=2015-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=25797, encodeId=668025e97c7, content=我有家人是患者, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=MedSci客户端网友, createdTime=Tue Jun 02 21:17:00 CST 2015, time=2015-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=25798, encodeId=95fa25e9864, content=那么如何调理呢, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=MedSci客户端网友, createdTime=Tue Jun 02 21:17:00 CST 2015, time=2015-06-02, status=1, ipAttribution=)]
    2016-09-08 ys2323

    收藏学习了

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=214403, encodeId=c23921440326, content=学习了,特别是对甲状腺微小癌的外科处理。, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NebL6HUuazlWRDicKU30ib7MWct2QQNWiao1ntOx2x5WUHGVw7R8NBdVuXbznuDsHKg3ImrnRyHGr8WSmKTnycicXEf/0, createdBy=bcd81373695, createdName=dpbl_zlh, createdTime=Fri Jun 23 15:10:49 CST 2017, time=2017-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=113575, encodeId=65d71135e5de, content=收藏学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160616/IMG5762A3665DC7B3997.jpg, createdBy=df0a1649089, createdName=ys2323, createdTime=Thu Sep 08 10:20:00 CST 2016, time=2016-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=25877, encodeId=677a258e79d, content=哈医大的啊, beContent=null, objectType=article, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0fb31625608, createdName=雨人, createdTime=Wed Jun 03 22:14:00 CST 2015, time=2015-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=25804, encodeId=3b472580494, content=新版的信息是从哪儿来的?子虚乌有?新版的ATA都没有不出来呢!!求说法, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=jasonuclear, createdTime=Tue Jun 02 23:19:00 CST 2015, time=2015-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=25799, encodeId=302c25e99b1, content=如何调理呢, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=06b51627034, createdName=荔枝, createdTime=Tue Jun 02 21:25:00 CST 2015, time=2015-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=25795, encodeId=e1cb25e951d, content=高大上, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=MedSci客户端网友, createdTime=Tue Jun 02 21:17:00 CST 2015, time=2015-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=25796, encodeId=200025e96b1, content=有点听不懂, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=MedSci客户端网友, createdTime=Tue Jun 02 21:17:00 CST 2015, time=2015-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=25797, encodeId=668025e97c7, content=我有家人是患者, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=MedSci客户端网友, createdTime=Tue Jun 02 21:17:00 CST 2015, time=2015-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=25798, encodeId=95fa25e9864, content=那么如何调理呢, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=MedSci客户端网友, createdTime=Tue Jun 02 21:17:00 CST 2015, time=2015-06-02, status=1, ipAttribution=)]
    2015-06-03 雨人

    哈医大的啊

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=214403, encodeId=c23921440326, content=学习了,特别是对甲状腺微小癌的外科处理。, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NebL6HUuazlWRDicKU30ib7MWct2QQNWiao1ntOx2x5WUHGVw7R8NBdVuXbznuDsHKg3ImrnRyHGr8WSmKTnycicXEf/0, createdBy=bcd81373695, createdName=dpbl_zlh, createdTime=Fri Jun 23 15:10:49 CST 2017, time=2017-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=113575, encodeId=65d71135e5de, content=收藏学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160616/IMG5762A3665DC7B3997.jpg, createdBy=df0a1649089, createdName=ys2323, createdTime=Thu Sep 08 10:20:00 CST 2016, time=2016-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=25877, encodeId=677a258e79d, content=哈医大的啊, beContent=null, objectType=article, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0fb31625608, createdName=雨人, createdTime=Wed Jun 03 22:14:00 CST 2015, time=2015-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=25804, encodeId=3b472580494, content=新版的信息是从哪儿来的?子虚乌有?新版的ATA都没有不出来呢!!求说法, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=jasonuclear, createdTime=Tue Jun 02 23:19:00 CST 2015, time=2015-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=25799, encodeId=302c25e99b1, content=如何调理呢, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=06b51627034, createdName=荔枝, createdTime=Tue Jun 02 21:25:00 CST 2015, time=2015-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=25795, encodeId=e1cb25e951d, content=高大上, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=MedSci客户端网友, createdTime=Tue Jun 02 21:17:00 CST 2015, time=2015-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=25796, encodeId=200025e96b1, content=有点听不懂, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=MedSci客户端网友, createdTime=Tue Jun 02 21:17:00 CST 2015, time=2015-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=25797, encodeId=668025e97c7, content=我有家人是患者, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=MedSci客户端网友, createdTime=Tue Jun 02 21:17:00 CST 2015, time=2015-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=25798, encodeId=95fa25e9864, content=那么如何调理呢, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=MedSci客户端网友, createdTime=Tue Jun 02 21:17:00 CST 2015, time=2015-06-02, status=1, ipAttribution=)]
    2015-06-02 jasonuclear

    新版的信息是从哪儿来的?子虚乌有?新版的ATA都没有不出来呢!!求说法

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=214403, encodeId=c23921440326, content=学习了,特别是对甲状腺微小癌的外科处理。, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NebL6HUuazlWRDicKU30ib7MWct2QQNWiao1ntOx2x5WUHGVw7R8NBdVuXbznuDsHKg3ImrnRyHGr8WSmKTnycicXEf/0, createdBy=bcd81373695, createdName=dpbl_zlh, createdTime=Fri Jun 23 15:10:49 CST 2017, time=2017-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=113575, encodeId=65d71135e5de, content=收藏学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160616/IMG5762A3665DC7B3997.jpg, createdBy=df0a1649089, createdName=ys2323, createdTime=Thu Sep 08 10:20:00 CST 2016, time=2016-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=25877, encodeId=677a258e79d, content=哈医大的啊, beContent=null, objectType=article, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0fb31625608, createdName=雨人, createdTime=Wed Jun 03 22:14:00 CST 2015, time=2015-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=25804, encodeId=3b472580494, content=新版的信息是从哪儿来的?子虚乌有?新版的ATA都没有不出来呢!!求说法, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=jasonuclear, createdTime=Tue Jun 02 23:19:00 CST 2015, time=2015-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=25799, encodeId=302c25e99b1, content=如何调理呢, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=06b51627034, createdName=荔枝, createdTime=Tue Jun 02 21:25:00 CST 2015, time=2015-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=25795, encodeId=e1cb25e951d, content=高大上, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=MedSci客户端网友, createdTime=Tue Jun 02 21:17:00 CST 2015, time=2015-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=25796, encodeId=200025e96b1, content=有点听不懂, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=MedSci客户端网友, createdTime=Tue Jun 02 21:17:00 CST 2015, time=2015-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=25797, encodeId=668025e97c7, content=我有家人是患者, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=MedSci客户端网友, createdTime=Tue Jun 02 21:17:00 CST 2015, time=2015-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=25798, encodeId=95fa25e9864, content=那么如何调理呢, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=MedSci客户端网友, createdTime=Tue Jun 02 21:17:00 CST 2015, time=2015-06-02, status=1, ipAttribution=)]
    2015-06-02 荔枝

    如何调理呢

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=214403, encodeId=c23921440326, content=学习了,特别是对甲状腺微小癌的外科处理。, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NebL6HUuazlWRDicKU30ib7MWct2QQNWiao1ntOx2x5WUHGVw7R8NBdVuXbznuDsHKg3ImrnRyHGr8WSmKTnycicXEf/0, createdBy=bcd81373695, createdName=dpbl_zlh, createdTime=Fri Jun 23 15:10:49 CST 2017, time=2017-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=113575, encodeId=65d71135e5de, content=收藏学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160616/IMG5762A3665DC7B3997.jpg, createdBy=df0a1649089, createdName=ys2323, createdTime=Thu Sep 08 10:20:00 CST 2016, time=2016-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=25877, encodeId=677a258e79d, content=哈医大的啊, beContent=null, objectType=article, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0fb31625608, createdName=雨人, createdTime=Wed Jun 03 22:14:00 CST 2015, time=2015-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=25804, encodeId=3b472580494, content=新版的信息是从哪儿来的?子虚乌有?新版的ATA都没有不出来呢!!求说法, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=jasonuclear, createdTime=Tue Jun 02 23:19:00 CST 2015, time=2015-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=25799, encodeId=302c25e99b1, content=如何调理呢, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=06b51627034, createdName=荔枝, createdTime=Tue Jun 02 21:25:00 CST 2015, time=2015-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=25795, encodeId=e1cb25e951d, content=高大上, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=MedSci客户端网友, createdTime=Tue Jun 02 21:17:00 CST 2015, time=2015-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=25796, encodeId=200025e96b1, content=有点听不懂, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=MedSci客户端网友, createdTime=Tue Jun 02 21:17:00 CST 2015, time=2015-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=25797, encodeId=668025e97c7, content=我有家人是患者, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=MedSci客户端网友, createdTime=Tue Jun 02 21:17:00 CST 2015, time=2015-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=25798, encodeId=95fa25e9864, content=那么如何调理呢, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=MedSci客户端网友, createdTime=Tue Jun 02 21:17:00 CST 2015, time=2015-06-02, status=1, ipAttribution=)]
    2015-06-02 MedSci客户端网友

    高大上

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=214403, encodeId=c23921440326, content=学习了,特别是对甲状腺微小癌的外科处理。, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NebL6HUuazlWRDicKU30ib7MWct2QQNWiao1ntOx2x5WUHGVw7R8NBdVuXbznuDsHKg3ImrnRyHGr8WSmKTnycicXEf/0, createdBy=bcd81373695, createdName=dpbl_zlh, createdTime=Fri Jun 23 15:10:49 CST 2017, time=2017-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=113575, encodeId=65d71135e5de, content=收藏学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160616/IMG5762A3665DC7B3997.jpg, createdBy=df0a1649089, createdName=ys2323, createdTime=Thu Sep 08 10:20:00 CST 2016, time=2016-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=25877, encodeId=677a258e79d, content=哈医大的啊, beContent=null, objectType=article, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0fb31625608, createdName=雨人, createdTime=Wed Jun 03 22:14:00 CST 2015, time=2015-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=25804, encodeId=3b472580494, content=新版的信息是从哪儿来的?子虚乌有?新版的ATA都没有不出来呢!!求说法, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=jasonuclear, createdTime=Tue Jun 02 23:19:00 CST 2015, time=2015-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=25799, encodeId=302c25e99b1, content=如何调理呢, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=06b51627034, createdName=荔枝, createdTime=Tue Jun 02 21:25:00 CST 2015, time=2015-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=25795, encodeId=e1cb25e951d, content=高大上, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=MedSci客户端网友, createdTime=Tue Jun 02 21:17:00 CST 2015, time=2015-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=25796, encodeId=200025e96b1, content=有点听不懂, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=MedSci客户端网友, createdTime=Tue Jun 02 21:17:00 CST 2015, time=2015-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=25797, encodeId=668025e97c7, content=我有家人是患者, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=MedSci客户端网友, createdTime=Tue Jun 02 21:17:00 CST 2015, time=2015-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=25798, encodeId=95fa25e9864, content=那么如何调理呢, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=MedSci客户端网友, createdTime=Tue Jun 02 21:17:00 CST 2015, time=2015-06-02, status=1, ipAttribution=)]
    2015-06-02 MedSci客户端网友

    有点听不懂

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=214403, encodeId=c23921440326, content=学习了,特别是对甲状腺微小癌的外科处理。, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NebL6HUuazlWRDicKU30ib7MWct2QQNWiao1ntOx2x5WUHGVw7R8NBdVuXbznuDsHKg3ImrnRyHGr8WSmKTnycicXEf/0, createdBy=bcd81373695, createdName=dpbl_zlh, createdTime=Fri Jun 23 15:10:49 CST 2017, time=2017-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=113575, encodeId=65d71135e5de, content=收藏学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160616/IMG5762A3665DC7B3997.jpg, createdBy=df0a1649089, createdName=ys2323, createdTime=Thu Sep 08 10:20:00 CST 2016, time=2016-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=25877, encodeId=677a258e79d, content=哈医大的啊, beContent=null, objectType=article, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0fb31625608, createdName=雨人, createdTime=Wed Jun 03 22:14:00 CST 2015, time=2015-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=25804, encodeId=3b472580494, content=新版的信息是从哪儿来的?子虚乌有?新版的ATA都没有不出来呢!!求说法, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=jasonuclear, createdTime=Tue Jun 02 23:19:00 CST 2015, time=2015-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=25799, encodeId=302c25e99b1, content=如何调理呢, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=06b51627034, createdName=荔枝, createdTime=Tue Jun 02 21:25:00 CST 2015, time=2015-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=25795, encodeId=e1cb25e951d, content=高大上, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=MedSci客户端网友, createdTime=Tue Jun 02 21:17:00 CST 2015, time=2015-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=25796, encodeId=200025e96b1, content=有点听不懂, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=MedSci客户端网友, createdTime=Tue Jun 02 21:17:00 CST 2015, time=2015-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=25797, encodeId=668025e97c7, content=我有家人是患者, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=MedSci客户端网友, createdTime=Tue Jun 02 21:17:00 CST 2015, time=2015-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=25798, encodeId=95fa25e9864, content=那么如何调理呢, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=MedSci客户端网友, createdTime=Tue Jun 02 21:17:00 CST 2015, time=2015-06-02, status=1, ipAttribution=)]
    2015-06-02 MedSci客户端网友

    我有家人是患者

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=214403, encodeId=c23921440326, content=学习了,特别是对甲状腺微小癌的外科处理。, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NebL6HUuazlWRDicKU30ib7MWct2QQNWiao1ntOx2x5WUHGVw7R8NBdVuXbznuDsHKg3ImrnRyHGr8WSmKTnycicXEf/0, createdBy=bcd81373695, createdName=dpbl_zlh, createdTime=Fri Jun 23 15:10:49 CST 2017, time=2017-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=113575, encodeId=65d71135e5de, content=收藏学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160616/IMG5762A3665DC7B3997.jpg, createdBy=df0a1649089, createdName=ys2323, createdTime=Thu Sep 08 10:20:00 CST 2016, time=2016-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=25877, encodeId=677a258e79d, content=哈医大的啊, beContent=null, objectType=article, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0fb31625608, createdName=雨人, createdTime=Wed Jun 03 22:14:00 CST 2015, time=2015-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=25804, encodeId=3b472580494, content=新版的信息是从哪儿来的?子虚乌有?新版的ATA都没有不出来呢!!求说法, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=jasonuclear, createdTime=Tue Jun 02 23:19:00 CST 2015, time=2015-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=25799, encodeId=302c25e99b1, content=如何调理呢, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=06b51627034, createdName=荔枝, createdTime=Tue Jun 02 21:25:00 CST 2015, time=2015-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=25795, encodeId=e1cb25e951d, content=高大上, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=MedSci客户端网友, createdTime=Tue Jun 02 21:17:00 CST 2015, time=2015-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=25796, encodeId=200025e96b1, content=有点听不懂, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=MedSci客户端网友, createdTime=Tue Jun 02 21:17:00 CST 2015, time=2015-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=25797, encodeId=668025e97c7, content=我有家人是患者, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=MedSci客户端网友, createdTime=Tue Jun 02 21:17:00 CST 2015, time=2015-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=25798, encodeId=95fa25e9864, content=那么如何调理呢, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=MedSci客户端网友, createdTime=Tue Jun 02 21:17:00 CST 2015, time=2015-06-02, status=1, ipAttribution=)]
    2015-06-02 MedSci客户端网友

    那么如何调理呢

    0

相关资讯

下载:2012甲状腺结节和分化型甲状腺癌诊治指南

  近日,2012 年10 月第28 卷第10 期《中华内分泌代谢杂志》刊登了我国首部《甲状腺结节和分化型甲状腺癌诊治指南》(以下简称指南)。   成人甲状腺结节的临床评估和处理流程图      图2 国际颈部六区分区法      分化型甲状腺癌(DTC )患者TSH 抑制治疗期间β受体阻滞剂的治疗指证      

JCEM:胰岛素抵抗与甲状腺结节血管化存在关联

研究背景: 胰岛素抵抗是甲状腺结节生长和进展的重要影响因素,可能与结节血管化的分布、组成及密度有关。 研究目的: 研究胰岛素抵抗与甲状腺结节血管化之间的关系。 研究设计: 2011年6月至11月,在中国南京开展了一项基于人群的横断面研究。 受试者: 研究共对40-79岁的10050名参与者进行检查,共检出2886例甲状腺结节患者,另纳入2532例符合纳入标

JAMA Intern Med:儿童期经历原子弹爆炸,可致老年期甲状腺结节

日本一项研究显示,儿童时期经历原子弹爆炸的幸存者,62~66年后出现辐射所致甲状腺结节。但辐射暴露与小的甲状腺结节无相关性。论文2014年12月31日在线发表于《美国医学会杂志·内科学》(JAMA Intern Med)。 研究纳入具备原子弹辐射剂量资料(平均剂量0.182Gy,中位数0.018Gy,剂量范围0~4.040Gy)的广岛和长崎原子弹爆炸幸存者2668名,爆炸时年龄均小

2012中国甲状腺结节和分化型甲状腺癌指南

前 言 甲状腺结节和甲状腺癌是内分泌系统的多发病和常见病。触诊获得的甲状腺结节患病率为3-7%,高分辨率B超检查获得的甲状腺结节的患病率为20-76%。甲状腺结节中的甲状腺癌的患病率为5-15%。近年来我国甲状腺癌的发病率呈现增高的趋势,非必要的甲状腺结节的手术率也显著升高。甲状腺癌的术式、放射性碘治疗、TSH抑制疗法和甲状腺癌复发的监测等方面都缺乏共识和规范。 甲状腺结节和甲状腺癌的诊断和治

AJCN:只吃无碘盐也会导致甲状腺结节

去年5月,国家卫计委下调碘盐浓度,由35mg/kg下调到25mg/kg,一年多来,杭州人群碘营养情况怎么样?杭州市疾控中心调查结果:杭州市人群碘营养处于正常状态适宜,但孕妇碘摄入低了,建议吃点海带紫菜汤。另外,研究发现,食用无碘盐与甲状腺结节患病风险增加有关,在女性中这种相关性更为明显。这一结果,发表在2013年9月份,美国营养学权威杂志《美国临床营养杂志》(American Journal of

Baidu
map
Baidu
map
Baidu
map